Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?: https://g.foolcdn.com/editorial/images/758866/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg
Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?

Pfizer (NYSE: PFE) stock has been in the dumps this year. It is struggling due to declining demand for its COVID products. And it may take some years before its top line starts rising meaningfully

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals: https://g.foolcdn.com/editorial/images/758926/scientists-lab-testing-blood-draw.jpg
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals

It's fair to say that Editas Medicine (NASDAQ: EDIT) is an ailing biotech. Over the past three years, its share price has fallen by 83% as it abandoned parts of its pipeline and laid off staff

Could CRISPR Therapeutics Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/758864/rich-couple-on-a-boat.jpg
Could CRISPR Therapeutics Stock Help You Become a Millionaire?

If you're looking for a stock that has the potential to grow your investment to $1 million, a good move may be to invest in a strong business that's in a fast-growing industry. Gene therapy is an

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?: https://g.foolcdn.com/editorial/images/758683/vertex.png
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?

Could the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a towering, innovative, and profitable growth business, as biopharma Vertex Pharmaceuticals (NASDAQ: VRTX)

Will UnitedHealth Group Be a Trillion-Dollar Stock by 2030?: https://g.foolcdn.com/editorial/images/758513/doctor-meeting-a-salesperson.jpg
Will UnitedHealth Group Be a Trillion-Dollar Stock by 2030?

UnitedHealth Group (NYSE: UNH) has a market capitalization of close to $500 billion and is one of the largest healthcare stocks you can invest in today. That means if it were to double in value, it

Where Will Regeneron Pharmaceuticals Be in 1 Year?: https://g.foolcdn.com/editorial/images/758512/a-team-of-scientists-reviewing-results-in-a-lab.jpg
Where Will Regeneron Pharmaceuticals Be in 1 Year?

Regeneron Pharmaceuticals (NASDAQ: REGN) is a growing biotech company that generates a ton of free cash flow. Over the years, it has obtained approval or authorization for 12 medicines. Its strong

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?: https://g.foolcdn.com/editorial/images/758888/a-person-delivering-a-presentation-getty.jpg
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?

Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (NASDAQ: CRSP) this year. The stock is up more than 60% in 2023 after the

Better Growth Stock: AbbVie vs. Abbott Laboratories: https://g.foolcdn.com/editorial/images/758510/doctor-showing-patient-a-chart.jpg
Better Growth Stock: AbbVie vs. Abbott Laboratories

Drugmaker AbbVie (NYSE: ABBV) spun off from Abbott Laboratories (NYSE: ABT) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue

The Top Healthcare Stocks to Buy With $100: https://g.foolcdn.com/editorial/images/758297/physician-talking-to-patient.jpg
The Top Healthcare Stocks to Buy With $100

How much money does one need to start investing in stocks? $1 million? $10,000? The truth is, even a relatively modest sum of $100 is enough to get started for two reasons. First, nowadays, it isn't

6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy: https://g.foolcdn.com/editorial/images/758499/scientists-studying-dna.jpg
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy

December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment

Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock: https://g.foolcdn.com/editorial/images/758640/dna-on-monitor-scientists.jpg
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock

"The thrill of victory and the agony of defeat."

That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR

Is Vertex Pharmaceuticals Sitting on a Gold Mine?: https://g.foolcdn.com/editorial/images/758783/gettyimages-two-researchers-work-in-a-lab.jpg
Is Vertex Pharmaceuticals Sitting on a Gold Mine?

Vertex Pharmaceuticals (NASDAQ: VRTX) has brought in billions of dollars in earnings over time thanks to its leadership in the market for cystic fibrosis (CF) treatment. And along with partner

This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know: https://g.foolcdn.com/editorial/images/758429/nvidia-headquarters-with-grey-nvidia-sign-in-front-with-nvidia-logo.png
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know

In late November, Roche's (OTC: RHHBY) subsidiary Genentech and the chipmaker Nvidia (NASDAQ: NVDA) agreed to collaborate on developing new medicines using artificial intelligence (AI) over the next

Better Dividend Stock: Pfizer or British American Tobacco?: https://g.foolcdn.com/editorial/images/758771/piggybank.jpg
Better Dividend Stock: Pfizer or British American Tobacco?

Dividend stocks offer attractive features for income and growth investors alike. On the income side, many blue chip dividend stocks sport higher yields than those of risk-free assets such as the

Want $1,500 in Dividend Income in 2024? Invest $25,000 in These 3 Top Income Stocks: https://g.foolcdn.com/editorial/images/758508/a-person-smiling-and-reviewing-their-finances.jpg
Want $1,500 in Dividend Income in 2024? Invest $25,000 in These 3 Top Income Stocks

Dividend income can boost your overall returns, and also provide you with some recurring cash flow for your portfolio. That's a good thing, because it means you don't have to sell your investments

3 Stocks Near Multiyear Lows That Could Bounce Back in 2024: https://g.foolcdn.com/editorial/images/758501/analyst-looking-at-charts.jpg
3 Stocks Near Multiyear Lows That Could Bounce Back in 2024

When a company underperforms, the markets sometimes have a tendency to overreact. An earnings miss or a guidance cut can at times be enough to lead to a significant sell-off, even if the underlying

3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/758605/investors-look-at-tablet-outside.jpg
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow

CRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their

Why Pfizer Stock Is Bouncing Back: https://g.foolcdn.com/editorial/images/758787/1-glowing-green-stock-arrow-climbs-on-a-stock-screen.jpg
Why Pfizer Stock Is Bouncing Back

For the third day in a row, shares of big pharma bellwether Pfizer (NYSE: PFE) are heading higher -- which is kind of curious. Just last week, Pfizer issued downbeat guidance for the year ahead. But

Why Pfizer Stock Was a Winner on Monday: https://g.foolcdn.com/editorial/images/758723/medical-professional-working-at-a-computer-terminal.jpg
Why Pfizer Stock Was a Winner on Monday

The success of drug developers hinges on regulatory approvals for their medications. Considering that, it was hardly surprising that Pfizer (NYSE: PFE) stock had a good Monday on the market

Pfizer Slashed Its Guidance, but Is It Still a Smart Long-Term Buy?: https://g.foolcdn.com/editorial/images/758430/investor-looks-at-book-with-consternation.jpg
Pfizer Slashed Its Guidance, but Is It Still a Smart Long-Term Buy?

Per updated guidance for its upcoming 2024 fiscal year, issued on Dec. 13, Pfizer (NYSE: PFE) has a bumpy road ahead -- at least for now. Amidst rapidly weakening coronavirus product revenue and

3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024: https://g.foolcdn.com/editorial/images/758417/woman-with-fingers-crossed-laptop.jpg
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024

Many investors will likely be wearing big smiles as 2023 winds down. The S&P 500 is on track to deliver a gain of over 20% and could hit an all-time high. The Nasdaq-100 has soared more than 50% and

1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond: https://g.foolcdn.com/editorial/images/758222/physician-giving-a-high-five-to-a-young-patient.jpg
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond

The word "revolutionary" sometimes gets thrown around a lot, but it certainly applies to Sarepta Therapeutics (NASDAQ: SRPT). This midcap biotech company has developed several treatments for

Is Amgen Stock a Buy Now?: https://g.foolcdn.com/editorial/images/757676/doctor-and-patient-talking.jpg
Is Amgen Stock a Buy Now?

This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen

Should You Worry About the Latest Wave of Bad News from Pfizer?: https://g.foolcdn.com/editorial/images/758421/gettyimages-613345556.jpg
Should You Worry About the Latest Wave of Bad News from Pfizer?

Earlier in the pandemic, Pfizer (NYSE: PFE) stood out as an earnings and stock-market star thanks to its leading coronavirus vaccine and treatment. But these days, those products are weighing on

CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?: https://g.foolcdn.com/editorial/images/758106/concerned-investor-with-two-people-in-background.jpg
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?

On Dec. 8, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals (NASDAQ: VRTX) made history when the Food and Drug Administration (FDA) gave them the green light